▶ 調査レポート

膀胱がん治療薬の世界市場研究

• 英文タイトル:Market Study on Bladder Cancer Treatment Drugs: Chemotherapy to Remain Leading Drug Type

Market Study on Bladder Cancer Treatment Drugs: Chemotherapy to Remain Leading Drug Type「膀胱がん治療薬の世界市場研究」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2306A023
• 出版社/出版日:Persistence Market Research / 2023年3月
• レポート形態:英文、PDF、394ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User License¥735,000 (USD4,900)▷ お問い合わせ
  Multi User License¥1,140,000 (USD7,600)▷ お問い合わせ
  Corporate License¥1,590,000 (USD10,600)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Persistence Market Research社の本調査レポートは、世界の膀胱がん治療薬市場を調査対象とし、エグゼクティブサマリー、市場概要、主要市場動向、価格分析、需要分析・予測、市場背景、市場構造分析、競争分析、仮定、調査手法などの構成でまとめております。セグメント分析では、がん種類別(筋層非浸潤性膀胱がん、筋層浸潤性膀胱がん)分析、悪性度別(低悪性度膀胱がん、高悪性度膀胱がん)分析、治療薬種類別(免疫療法、カルメットゲリン桿菌、アベルマブ、ニボルマブ、その他)分析、化学療法別(マイトマイシンC、ドセタキセル、パクリタキセル、シスプラチン、その他)分析、地域別(北米、中南米、ヨーロッパ、東アジア、南アジア、オセアニア、中東・アフリカ)分析などの内容を掲載しています。なお、本レポートには、Pfizer Inc.、Merck KGaA、Merck & Co、AstraZeneca PLC、Roche Holding AG(Genentech)、Astellas Pharma Inc.、J&J(Janssen Biotech)、Cipla Inc.、Amneal Pharma、Bristol Myers Squibb Co.、Dr. Reddy’s Laboratories, Inc.、Gilead Sciences Inc.、Endo Pharma、UroGen Pharma, Inc.などの企業情報が含まれています。

・エグゼクティブサマリー
・市場概要
・主要市場動向
・価格分析
・需要分析・予測
・市場背景
・世界の膀胱がん治療薬市場規模:がん種類別
- 筋層非浸潤性膀胱がんの市場規模
- 筋層浸潤性膀胱がんの市場規模
・世界の膀胱がん治療薬市場規模:悪性度別
- 低悪性度膀胱がんの市場規模
- 高悪性度膀胱がんの市場規模
・世界の膀胱がん治療薬市場規模:治療薬種類別
- 免疫療法の市場規模
- カルメットゲリン桿菌の市場規模
- アベルマブの市場規模
- ニボルマブの市場規模
- その他治療薬種類の市場規模
・世界の膀胱がん治療薬市場規模:化学療法分析
- マイトマイシンCの市場規模
- ドセタキセルの市場規模
- パクリタキセルの市場規模
- シスプラチンの市場規模
- その他化学療法の市場規模
・世界の膀胱がん治療薬市場規模:地域別
- 北米の膀胱がん治療薬市場規模
- 中南米の膀胱がん治療薬市場規模
- ヨーロッパの膀胱がん治療薬市場規模
- 東アジアの膀胱がん治療薬市場規模
- 南アジアの膀胱がん治療薬市場規模
- オセアニアの膀胱がん治療薬市場規模
- 中東・アフリカの膀胱がん治療薬市場規模
・市場構造分析
・競争分析
・仮定
・調査方法

Bladder Cancer Treatment Drugs Market – Report Scope

The latest publication by Persistence Market Research on the global bladder cancer treatment drugs market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights into current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2023 to 2033.

Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research’s study. This research study can support readers to know the demand for bladder cancer treatment drugs and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the bladder cancer treatment drugs market. Insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the bladder cancer treatment drugs market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics, as well as information linked to the macro- as well as macroeconomic variables affecting the business scenario in the bladder cancer treatment drugs market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments

Persistence Market Research’s study on the bladder cancer treatment drugs market offers information divided into five important segments – cancer type, cancer grade, drug type, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Cancer Type
Non-Muscle-Invasive Bladder Cancer
Muscle-Invasive Bladder Cancer

Cancer Grade
Low-Grade Bladder Cancer
High-Grade Bladder Cancer

Drug Type
Immunotherapy
Bacillus Calmette-Guerin
Avelumab
Nivolumab
Pembrolizumab
Others

Chemotherapy
Mitomycin C
Docetaxel
Paclitaxel
Cisplatin
Others

Targeted Therapy
Erdafitinib
Enfortumab vedotin-ejfv
Sacituzumab govitecan
Others

Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Specialty Pharmacies
Online Pharmacies

Region
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

Key Questions Answered in Study
Which regions will continue to remain the most profitable markets for bladder cancer treatment drug manufacturers over the coming years?
How will changing trends impact the market?
How has the COVID-19 crisis impacted market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will impact the market?
How can companies in the bladder cancer treatment drugs market avail themselves of the growth opportunities in developed and emerging sectors?

Research Methodology
In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the bladder cancer treatment drugs market and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research’s projections on the growth prospects of the bladder cancer treatment drugs market more accurate and reliable.

レポート目次

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Key Market Trends

    3.1. Key Trends Impacting the Market

4. Key Success Factors

    4.1. Product Adoption Analysis

    4.2. Key Strategies, by Manufacturers

    4.3. Regulatory Scenario

    4.4. Porters Analysis

    4.5. PESTLE Analysis

    4.6. Supply Chain Analysis

    4.7. Funding In Research & Development

    4.8. Clinical Trials Analysis

    4.9. Pipeline Analysis

    4.10. Disease Epidemiology, by Region

    4.11. Reimbursement Scenario

    4.12. Parent Market Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Pharmaceutical Industry Overview

    5.2. Forecast Factors – Relevance & Impact

        5.2.1. Rising Healthcare Spending

        5.2.2. Increasing Prevalence of Cancer

        5.2.3. Increasing Awareness and Supportive Government Initiatives

        5.2.4. Increase in Funding for

        5.2.5. Cancer Research

        5.2.6. Increase In Product Launches

        5.2.7. Strong Product Pipeline

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. COVID-19 Crisis – Impact Assessment

        6.1.1. Impact of COVID-19 – 2021 Market Scenario

        6.1.2. COVID-19 Impact Summary

7. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012-2022 and Forecast, 2023-2033

    7.1. Historical Market Value (US$ Mn) Analysis, 2012-2022

    7.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Bladder Cancer Type

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis by Bladder Cancer Type, 2012-2022

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Bladder Cancer Type, 2023-2033

        8.3.1. Non-Muscle-Invasive Bladder Cancer

        8.3.2. Muscle-Invasive Bladder Cancer

    8.4. Market Attractiveness Analysis by Bladder Cancer Type

9. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Cancer grade

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis by Cancer grade, 2012-2022

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Cancer grade, 2023-2033

        9.3.1. Low-grade bladder cancer

        9.3.2. High-grade bladder cancer

    9.4. Market Attractiveness Analysis by Cancer grade

10. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Drug Type

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis by Drug Type, 2012-2022

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Drug Type, 2023-2033

        10.3.1. Immunotherapy

            10.3.1.1. Bacillus Calmette-Guerin

            10.3.1.2. Avelumab

            10.3.1.3. Nivolumab

            10.3.1.4. Pembrolizumab

            10.3.1.5. Others

        10.3.2. Chemotherapy

            10.3.2.1. Mitomycin C

            10.3.2.2. Docetaxel

            10.3.2.3. Paclitaxel

            10.3.2.4. Cisplatin

            10.3.2.5. Others

        10.3.3. Targeted therapy

            10.3.3.1. Erdafitinib

            10.3.3.2. Enfortumab vedotin-ejfv

            10.3.3.3. Sacituzumab govitecan

            10.3.3.4. Others

    10.4. Market Attractiveness Analysis by Drug Type

11. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Distribution Channel

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2022

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2023-2033

        11.3.1. Hospital Pharmacy

        11.3.2. Retail Pharmacy

        11.3.3. Specialty Pharmacy

        11.3.4. Online Pharmacy

    11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Market Analysis 2012-2022 and Forecast 2023-2033, by Region

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Analysis By Region, 2012-2022

    12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2023-2033

        12.3.1. North America

        12.3.2. Latin America

        12.3.3. Europe

        12.3.4. East Asia

        12.3.5. South Asia

        12.3.6. Oceania

        12.3.7. Middle East and Africa (MEA)

    12.4. Market Attractiveness Analysis By Region

13. North America Market Analysis 2012-2022 and Forecast 2023-2033

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis, By Market Taxonomy, 2012-2022

    13.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy 2023-2033

        13.3.1. By Country

            13.3.1.1. U.S.

            13.3.1.2. Canada

        13.3.2. By Bladder Cancer Type

        13.3.3. By Cancer Grade

        13.3.4. By Drug Type

        13.3.5. By Distribution Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Bladder Cancer Type

        13.4.3. By Cancer Grade

        13.4.4. By Drug Type

        13.4.5. By Distribution Channel

    13.5. Key Market Participants – Intensity Mapping

    13.6. Drivers and Restraints – Impact Analysis

    13.7. Country-Level Analysis & Forecast

        13.7.1. U.S. Market Analysis

            13.7.1.1. .Introduction

            13.7.1.2. Market Analysis and Forecast by Market Taxonomy

                13.7.1.2.1. By Bladder Cancer Type

                13.7.1.2.2. By Cancer Grade

                13.7.1.2.3. By Drug Type

                13.7.1.2.4. By Distribution Channel

        13.7.2. Canada Market Analysis

            13.7.2.1. Introduction

            13.7.2.2. Market Analysis and Forecast by Market Taxonomy

                13.7.2.2.1. By Bladder Cancer Type

                13.7.2.2.2. By Cancer Grade

                13.7.2.2.3. By Drug Type

                13.7.2.2.4. By Distribution Channel

14. Latin America Market Analysis 2012-2022 and Forecast 2023-2033

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022

    14.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033

        14.3.1. By Country

            14.3.1.1. Mexico

            14.3.1.2. Brazil

            14.3.1.3. Argentina

            14.3.1.4. Rest of Latin America

        14.3.2. By Bladder Cancer Type

        14.3.3. By Cancer Grade

        14.3.4. By Drug Type

        14.3.5. By Distribution Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Bladder Cancer Type

        14.4.3. By Cancer Grade

        14.4.4. By Drug Type

        14.4.5. By Distribution Channel

    14.5. Key Market Participants – Intensity Mapping

    14.6. Drivers and Restraints – Impact Analysis

    14.7. Country-Level Analysis & Forecast

        14.7.1. Mexico Market Analysis

            14.7.1.1. Introduction

            14.7.1.2. Market Analysis and Forecast by Market Taxonomy

                14.7.1.2.1. By Bladder Cancer Type

                14.7.1.2.2. By Cancer Grade

                14.7.1.2.3. By Drug Type

                14.7.1.2.4. By Distribution Channel

        14.7.2. Brazil Market Analysis

            14.7.2.1. Introduction

            14.7.2.2. Market Analysis and Forecast by Market Taxonomy

                14.7.2.2.1. By Bladder Cancer Type

                14.7.2.2.2. By Cancer Grade

                14.7.2.2.3. By Drug Type

                14.7.2.2.4. By Distribution Channel

        14.7.3. Argentina Market Analysis

            14.7.3.1. Introduction

            14.7.3.2. Market Analysis and Forecast by Market Taxonomy

                14.7.3.2.1. By Bladder Cancer Type

                14.7.3.2.2. By Cancer Grade

                14.7.3.2.3. By Drug Type

                14.7.3.2.4. By Distribution Channel

15. Europe Market Analysis 2012-2022 and Forecast 2023-2033

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Analysis, By Market Taxonomy, 2012-2022

    15.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033

        15.3.1. By Country

            15.3.1.1. Germany

            15.3.1.2. Italy

            15.3.1.3. France

            15.3.1.4. U.K.

            15.3.1.5. Spain

            15.3.1.6. Poland

            15.3.1.7. Russia

            15.3.1.8. Rest of Europe

        15.3.2. By Bladder Cancer Type

        15.3.3. By Cancer Grade

        15.3.4. By Drug Type

        15.3.5. By Distribution Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Bladder Cancer Type

        15.4.3. By Cancer Grade

        15.4.4. By Drug Type

        15.4.5. By Distribution Channel

    15.5. Key Market Participants – Intensity Mapping

    15.6. Drivers and Restraints – Impact Analysis

    15.7. Country-Level Analysis & Forecast

        15.7.1. Germany Market Analysis

            15.7.1.1. Introduction

            15.7.1.2. Market Analysis and Forecast by Market Taxonomy

                15.7.1.2.1. By Bladder Cancer Type

                15.7.1.2.2. By Cancer Grade

                15.7.1.2.3. By Drug Type

                15.7.1.2.4. By Distribution Channel

        15.7.2. Italy Market Analysis

            15.7.2.1. Introduction

            15.7.2.2. Market Analysis and Forecast by Market Taxonomy

                15.7.2.2.1. By Bladder Cancer Type

                15.7.2.2.2. By Cancer Grade

                15.7.2.2.3. By Drug Type

                15.7.2.2.4. By Distribution Channel

        15.7.3. France Market Analysis

            15.7.3.1. Introduction

            15.7.3.2. Market Analysis and Forecast by Market Taxonomy

                15.7.3.2.1. By Bladder Cancer Type

                15.7.3.2.2. By Cancer Grade

                15.7.3.2.3. By Drug Type

                15.7.3.2.4. By Distribution Channel

        15.7.4. U.K. Market Analysis

            15.7.4.1. Introduction

            15.7.4.2. Market Analysis and Forecast by Market Taxonomy

                15.7.4.2.1. By Bladder Cancer Type

                15.7.4.2.2. By Cancer Grade

                15.7.4.2.3. By Drug Type

                15.7.4.2.4. By Distribution Channel

        15.7.5. Spain Market Analysis

            15.7.5.1. Introduction

            15.7.5.2. Market Analysis and Forecast by Market Taxonomy

                15.7.5.2.1. By Bladder Cancer Type

                15.7.5.2.2. By Cancer Grade

                15.7.5.2.3. By Drug Type

                15.7.5.2.4. By Distribution Channel

        15.7.6. Poland Market Analysis

            15.7.6.1. Introduction

            15.7.6.2. Market Analysis and Forecast by Market Taxonomy

                15.7.6.2.1. By Bladder Cancer Type

                15.7.6.2.2. By Cancer Grade

                15.7.6.2.3. By Drug Type

                15.7.6.2.4. By Distribution Channel

        15.7.7. Russia Market Analysis

            15.7.7.1. Introduction

            15.7.7.2. Market Analysis and Forecast by Market Taxonomy

                15.7.7.2.1. By Bladder Cancer Type

                15.7.7.2.2. By Cancer Grade

                15.7.7.2.3. By Drug Type

                15.7.7.2.4. By Distribution Channel

16. South Asia Market Analysis 2012-2022 and Forecast 2023-2033

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022

    16.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033

        16.3.1. By Country

            16.3.1.1. India

            16.3.1.2. Indonesia

            16.3.1.3. Malaysia

            16.3.1.4. Thailand

            16.3.1.5. Rest of South Asia

        16.3.2. By Bladder Cancer Type

        16.3.3. By Cancer Grade

        16.3.4. By Drug Type

        16.3.5. By Distribution Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Bladder Cancer Type

        16.4.3. By Cancer Grade

        16.4.4. By Drug Type

        16.4.5. By Distribution Channel

    16.5. Key Market Participants – Intensity Mapping

    16.6. Drivers and Restraints – Impact Analysis

    16.7. Country-Level Analysis & Forecast

        16.7.1. India Market Analysis

            16.7.1.1. Introduction

            16.7.1.2. Market Analysis and Forecast by Market Taxonomy

                16.7.1.2.1. By Bladder Cancer Type

                16.7.1.2.2. By Cancer Grade

                16.7.1.2.3. By Drug Type

                16.7.1.2.4. By Distribution Channel

        16.7.2. Indonesia Market Analysis

            16.7.2.1. Introduction

            16.7.2.2. Market Analysis and Forecast by Market Taxonomy

                16.7.2.2.1. By Bladder Cancer Type

                16.7.2.2.2. By Cancer Grade

                16.7.2.2.3. By Drug Type

                16.7.2.2.4. By Distribution Channel

        16.7.3. Malaysia Market Analysis

            16.7.3.1. Introduction

            16.7.3.2. Market Analysis and Forecast by Market Taxonomy

                16.7.3.2.1. By Bladder Cancer Type

                16.7.3.2.2. By Cancer Grade

                16.7.3.2.3. By Drug Type

                16.7.3.2.4. By Distribution Channel

        16.7.4. Thailand Market Analysis

            16.7.4.1. Introduction

            16.7.4.2. Market Analysis and Forecast by Market Taxonomy

                16.7.4.2.1. By Bladder Cancer Type

                16.7.4.2.2. By Cancer Grade

                16.7.4.2.3. By Drug Type

                16.7.4.2.4. By Distribution Channel

17. East Asia Market Analysis 2012-2022 and Forecast 2023-2033

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022

    17.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033

        17.3.1. By Country

            17.3.1.1. China

            17.3.1.2. Japan

            17.3.1.3. South Korea

        17.3.2. By Bladder Cancer Type

        17.3.3. By Cancer Grade

        17.3.4. By Drug Type

        17.3.5. By Distribution Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Bladder Cancer Type

        17.4.3. By Cancer Grade

        17.4.4. By Drug Type

        17.4.5. By Distribution Channel

    17.5. Key Market Participants – Intensity Mapping

    17.6. Drivers and Restraints – Impact Analysis

    17.7. Country-Level Analysis & Forecast

        17.7.1. China Market Analysis

            17.7.1.1. Introduction

            17.7.1.2. Market Analysis and Forecast by Market Taxonomy

                17.7.1.2.1. By Bladder Cancer Type

                17.7.1.2.2. By Cancer Grade

                17.7.1.2.3. By Drug Type

                17.7.1.2.4. By Distribution Channel

        17.7.2. Japan Market Analysis

            17.7.2.1. Introduction

            17.7.2.2. Market Analysis and Forecast by Market Taxonomy

                17.7.2.2.1. By Bladder Cancer Type

                17.7.2.2.2. By Cancer Grade

                17.7.2.2.3. By Drug Type

                17.7.2.2.4. By Distribution Channel

        17.7.3. South Korea Drugs Market Analysis

            17.7.3.1. Introduction

            17.7.3.2. Market Analysis and Forecast by Market Taxonomy

                17.7.3.2.1. By Bladder Cancer Type

                17.7.3.2.2. By Cancer Grade

                17.7.3.2.3. By Drug Type

                17.7.3.2.4. By Distribution Channel

18. Oceania Market 2012-2022 and Forecast 2022-2033

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2012-2022

    18.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033

        18.3.1. By Country

            18.3.1.1. Australia

            18.3.1.2. New Zealand

        18.3.2. By Bladder Cancer Type

        18.3.3. By Cancer Grade

        18.3.4. By Drug Type

        18.3.5. By Distribution Channel

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Bladder Cancer Type

        18.4.3. By Cancer Grade

        18.4.4. By Drug Type

        18.4.5. By Distribution Channel

    18.5. Key Market Participants – Intensity Mapping

    18.6. Drivers and Restraints – Impact Analysis

    18.7. Country-Level Analysis & Forecast

        18.7.1. Australia Market Analysis

            18.7.1.1. Introduction

            18.7.1.2. Market Analysis and Forecast by Market Taxonomy

                18.7.1.2.1. By Bladder Cancer Type

                18.7.1.2.2. By Cancer Grade

                18.7.1.2.3. By Drug Type

                18.7.1.2.4. By Distribution Channel

        18.7.2. New Zealand Market Analysis

            18.7.2.1. Introduction

            18.7.2.2. Market Analysis and Forecast by Market Taxonomy

                18.7.2.2.1. By Bladder Cancer Type

                18.7.2.2.2. By Cancer Grade

                18.7.2.2.3. By Drug Type

                18.7.2.2.4. By Distribution Channel

19. Middle East and Africa (MEA) Market Analysis 2012-2022 and Forecast 2023-2033

    19.1. Introduction

    19.2. Historical Market Size (US$ Mn) and Trend Analysis By Market Taxonomy, 2012-2022

    19.3. Current and Future Market Size (US$ Mn) Analysis, By Market Taxonomy, 2023-2033

        19.3.1. By Country

            19.3.1.1. GCC Countries

            19.3.1.2. South Africa

            19.3.1.3. North Africa

            19.3.1.4. Türkiye

            19.3.1.5. Rest of Middle East and Africa

        19.3.2. By Bladder Cancer Type

        19.3.3. By Cancer Grade

        19.3.4. By Drug Type

        19.3.5. By Distribution Channel

    19.4. Market Attractiveness Analysis

        19.4.1. By Country

        19.4.2. By Bladder Cancer Type

        19.4.3. By Cancer Grade

        19.4.4. By Drug Type

        19.4.5. By Distribution Channel

    19.5. Key Market Participants – Intensity Mapping

    19.6. Drivers and Restraints – Impact Analysis

    19.7. Country-Level Analysis & Forecast

        19.7.1. GCC Countries Market Analysis

            19.7.1.1. Introduction

            19.7.1.2. Market Analysis and Forecast by Market Taxonomy

                19.7.1.2.1. By Bladder Cancer Type

                19.7.1.2.2. By Cancer Grade

                19.7.1.2.3. By Drug Type

                19.7.1.2.4. By Distribution Channel

        19.7.2. South Africa Market Analysis

            19.7.2.1. Introduction

            19.7.2.2. Market Analysis and Forecast by Market Taxonomy

                19.7.2.2.1. By Bladder Cancer Type

                19.7.2.2.2. By Cancer Grade

                19.7.2.2.3. By Drug Type

                19.7.2.2.4. By Distribution Channel

        19.7.3. North Africa Market Analysis

            19.7.3.1. Introduction

            19.7.3.2. Market Analysis and Forecast by Market Taxonomy

                19.7.3.2.1. By Bladder Cancer Type

                19.7.3.2.2. By Cancer Grade

                19.7.3.2.3. By Drug Type

                19.7.3.2.4. By Distribution Channel

        19.7.4. Türkiye Market Analysis

            19.7.4.1. Introduction

            19.7.4.2. Market Analysis and Forecast by Market Taxonomy

                19.7.4.2.1. By Bladder Cancer Type

                19.7.4.2.2. By Cancer Grade

                19.7.4.2.3. By Drug Type

                19.7.4.2.4. By Distribution Channel

20. Market Structure Analysis

    20.1. Market Analysis by Tier of Companies

    20.2. Market Share Analysis of Top Players

    20.3. Market Presence Analysis

        20.3.1. By Regional footprint of Players

        20.3.2. Product footprint by Players

        20.3.3. Channel Foot Print by Players

21. Competition Analysis

    21.1. Competition Dashboard

    21.2. Competition Benchmarking

    21.3. Competition Deep Dive [Tentative list]

        21.3.1. Pfizer Inc.

            21.3.1.1. Overview

            21.3.1.2. Product Portfolio

            21.3.1.3. Business Segment Overview

            21.3.1.4. Sales Footprint

            21.3.1.5. SWOT Analysis

            21.3.1.6. Key Financials

            21.3.1.7. Strategy Overview

        21.3.2. Merck KGaA

            21.3.2.1. Overview

            21.3.2.2. Product Portfolio

            21.3.2.3. Business Segment Overview

            21.3.2.4. Sales Footprint

            21.3.2.5. SWOT Analysis

            21.3.2.6. Key Financials

            21.3.2.7. Strategy Overview

        21.3.3. Merck & Co

            21.3.3.1. Overview

            21.3.3.2. Product Portfolio

            21.3.3.3. Business Segment Overview

            21.3.3.4. Sales Footprint

            21.3.3.5. SWOT Analysis

            21.3.3.6. Key Financials

            21.3.3.7. Strategy Overview

        21.3.4. AstraZeneca PLC

            21.3.4.1. Overview

            21.3.4.2. Product Portfolio

            21.3.4.3. Business Segment Overview

            21.3.4.4. Sales Footprint

            21.3.4.5. SWOT Analysis

            21.3.4.6. Key Financials

            21.3.4.7. Strategy Overview

        21.3.5. Roche Holding AG (Genentech)

            21.3.5.1. Overview

            21.3.5.2. Product Portfolio

            21.3.5.3. Business Segment Overview

            21.3.5.4. Sales Footprint

            21.3.5.5. SWOT Analysis

            21.3.5.6. Key Financials

            21.3.5.7. Strategy Overview

        21.3.6. Astellas Pharma Inc.

            21.3.6.1. Overview

            21.3.6.2. Product Portfolio

            21.3.6.3. Business Segment Overview

            21.3.6.4. Sales Footprint

            21.3.6.5. SWOT Analysis

            21.3.6.6. Key Financials

            21.3.6.7. Strategy Overview

        21.3.7. J&J (Janssen Biotech)

            21.3.7.1. Overview

            21.3.7.2. Product Portfolio

            21.3.7.3. Business Segment Overview

            21.3.7.4. Sales Footprint

            21.3.7.5. SWOT Analysis

            21.3.7.6. Key Financials

            21.3.7.7. Strategy Overview

        21.3.8. Cipla Inc.

            21.3.8.1. Overview

            21.3.8.2. Product Portfolio

            21.3.8.3. Business Segment Overview

            21.3.8.4. Sales Footprint

            21.3.8.5. SWOT Analysis

            21.3.8.6. Key Financials

            21.3.8.7. Strategy Overview

        21.3.9. Amneal Pharma

            21.3.9.1. Overview

            21.3.9.2. Product Portfolio

            21.3.9.3. Business Segment Overview

            21.3.9.4. Sales Footprint

            21.3.9.5. SWOT Analysis

            21.3.9.6. Key Financials

            21.3.9.7. Strategy Overview

        21.3.10. Bristol Myers Squibb Co.

            21.3.10.1. Overview

            21.3.10.2. Product Portfolio

            21.3.10.3. Business Segment Overview

            21.3.10.4. Sales Footprint

            21.3.10.5. SWOT Analysis

            21.3.10.6. Key Financials

            21.3.10.7. Strategy Overview

        21.3.11. Dr. Reddy’s Laboratories, Inc.

            21.3.11.1. Overview

            21.3.11.2. Product Portfolio

            21.3.11.3. Business Segment Overview

            21.3.11.4. Sales Footprint

            21.3.11.5. SWOT Analysis

            21.3.11.6. Key Financials

            21.3.11.7. Strategy Overview

        21.3.12. Gilead Sciences Inc.

            21.3.12.1. Overview

            21.3.12.2. Product Portfolio

            21.3.12.3. Business Segment Overview

            21.3.12.4. Sales Footprint

            21.3.12.5. SWOT Analysis

            21.3.12.6. Key Financials

            21.3.12.7. Strategy Overview

        21.3.13. Endo Pharma

            21.3.13.1. Overview

            21.3.13.2. Product Portfolio

            21.3.13.3. Business Segment Overview

            21.3.13.4. Sales Footprint

            21.3.13.5. SWOT Analysis

            21.3.13.6. Key Financials

            21.3.13.7. Strategy Overview

        21.3.14. UroGen Pharma, Inc.

            21.3.14.1. Overview

            21.3.14.2. Product Portfolio

            21.3.14.3. Business Segment Overview

            21.3.14.4. Sales Footprint

            21.3.14.5. SWOT Analysis

            21.3.14.6. Key Financials

            21.3.14.7. Strategy Overview

        21.3.15. Teva Pharmaceuticals (Actavis)

            21.3.15.1. Overview

            21.3.15.2. Product Portfolio

            21.3.15.3. Business Segment Overview

            21.3.15.4. Sales Footprint

            21.3.15.5. SWOT Analysis

            21.3.15.6. Key Financials

            21.3.15.7. Strategy Overview

        21.3.16. Hikma Pharmaceuticals

            21.3.16.1. Overview

            21.3.16.2. Product Portfolio

            21.3.16.3. Business Segment Overview

            21.3.16.4. Sales Footprint

            21.3.16.5. SWOT Analysis

            21.3.16.6. Key Financials

            21.3.16.7. Strategy Overview

        21.3.17. Incyte

            21.3.17.1. Overview

            21.3.17.2. Product Portfolio

            21.3.17.3. Business Segment Overview

            21.3.17.4. Sales Footprint

            21.3.17.5. SWOT Analysis

            21.3.17.6. Key Financials

            21.3.17.7. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology

Table 01: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 02: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 03: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 04: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 05: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 06: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 07: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 08: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 09: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Region

Table 10: Global Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Region

Table 11: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 12: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country

Table 13: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 14: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 15: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 16: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 17: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 18: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 19: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 20: North America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 21: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 22: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country

Table 23: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 24: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 25: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 26: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 27: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 28: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 29: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 30: Latin America Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 31: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 32: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country

Table 33: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 34: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 35: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 36: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 37: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 38: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 39: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 40: Europe Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 41: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 42: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country

Table 43: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 44: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 45: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 46: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 47: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 48: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 49: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 50: South Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 51: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 52: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country

Table 53: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 54: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 55: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 56: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 57: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 58: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 59: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 60: East Asia Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 61: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 62: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Country

Table 63: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 64: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 65: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 66: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 67: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 68: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 69: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 70: Oceania Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel

Table 71: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 72: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Country

Table 73: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Bladder Cancer Type

Table 74: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Bladder Cancer Type

Table 75: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Cancer Grade

Table 76: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Cancer Grade

Table 77: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, by Drug Type

Table 78: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, by Drug Type

Table 79: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Analysis 2012-2022, By Distribution Channel

Table 80: Middle East & Africa Bladder Cancer Treatment Drugs Market Value (US$ Mn) Opportunity Assessment 2023-2033, By Distribution Channel